دورية أكاديمية

Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome

التفاصيل البيبلوغرافية
العنوان: Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome
المؤلفون: Musokhranova, Uliana, Grau, Cristina, Vergara, Cristina, Rodríguez-Pascau, Laura, Xiol, Clara, Castells, Alba A, Alcántara, Soledad, Rodríguez-Pombo, Pilar, Pizcueta, Pilar, Martinell, Marc, García-Cazorla, Angels, Oyarzábal, Alfonso
المساهمون: Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Generalitat de Catalunya, Mi Princesa Rett
بيانات النشر: BioMed Central
سنة النشر: 2023
المجموعة: Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council)
الوصف: Background: Rett syndrome is a neuropediatric disease occurring due to mutations in MECP2 and characterized by a regression in the neuronal development following a normal postnatal growth, which results in the loss of acquired capabilities such as speech or purposeful usage of hands. While altered neurotransmission and brain development are the center of its pathophysiology, alterations in mitochondrial performance have been previously outlined, shaping it as an attractive target for the disease treatment. Methods: We have thoroughly described mitochondrial performance in two Rett models, patients’ primary fibroblasts and female Mecp2 mice brain, discriminating between different brain areas. The characterization was made according to their bioenergetics function, oxidative stress, network dynamics or ultrastructure. Building on that, we have studied the effect of leriglitazone, a PPARγ agonist, in the modulation of mitochondrial performance. For that, we treated Rett female mice with 75 mg/kg/day leriglitazone from weaning until sacrifice at 7 months, studying both the mitochondrial performance changes and their consequences on the mice phenotype. Finally, we studied its effect on neuroinflammation based on the presence of reactive glia by immunohistochemistry and through a cytokine panel. Results: We have described mitochondrial alterations in Rett fibroblasts regarding both shape and bioenergetic functions, as they displayed less interconnected and shorter mitochondria and reduced ATP production along with increased oxidative stress. The bioenergetic alterations were recalled in Rett mice models, being especially significant in cerebellum, already detectable in pre-symptomatic stages. Treatment with leriglitazone recovered the bioenergetic alterations both in Rett fibroblasts and female mice and exerted an anti-inflammatory effect in the latest, resulting in the amelioration of the mice phenotype both in general condition and exploratory activity. Conclusions: Our studies confirm the mitochondrial dysfunction ...
نوع الوثيقة: article in journal/newspaper
اللغة: unknown
تدمد: 1479-5876
العلاقة: #PLACEHOLDER_PARENT_METADATA_VALUE#; info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-115748RB-I00/ES/MODELADO DEL CONTROL AMBIENTAL DE LA DIFERENCIACION DE LOS PROGENITORES NEURALES: UN PUNTO DE ENCUENTRO ENTRE LOS TRASTORNOS DEL DESARROLLO Y LA REGENERACION NEURAL/; info:eu-repo/grantAgreement/Generalitat de Catalunya “PIF-Salut” Grant PFP00201-PERIS (UM, AGC, AO); info:eu-repo/grantAgreement/Princesa Rett and Rettando al Síndrome de Rett donations (AGC, AO, UM, CG, CX); Publisher's version; http://dx.doi.org/10.1186/s12967-023-04622-5Test; Sí; Journal of Translational Medicine 21 (2023); http://hdl.handle.net/10261/357526Test; http://dx.doi.org/10.13039/501100011033Test; http://dx.doi.org/10.13039/501100002809Test; http://dx.doi.org/10.13039/501100004837Test
DOI: 10.1186/s12967-023-04622-5
DOI: 10.13039/501100011033
DOI: 10.13039/501100002809
DOI: 10.13039/501100004837
الإتاحة: https://doi.org/10.1186/s12967-023-04622-510.13039/50110001103310.13039/50110000280910.13039/501100004837Test
http://hdl.handle.net/10261/357526Test
حقوق: open
رقم الانضمام: edsbas.DD457CE5
قاعدة البيانات: BASE
الوصف
تدمد:14795876
DOI:10.1186/s12967-023-04622-5